Federal regulators have approved a revolutionary pancreatic cancer treatment that doubles patient survival times, marking the first major breakthrough against one of America’s deadliest diseases in decades.
Historic Approval for Deadly Disease
The Food and Drug Administration approved Rasonque on Wednesday for patients with advanced pancreatic cancer who have tried prior treatments. The drug, manufactured by Revolution Medicines, demonstrated remarkable results in clinical trials involving 500 patients. Those receiving Rasonque alongside standard chemotherapy survived an average of 13.2 months, compared to roughly half that time for patients receiving chemotherapy alone. The approval represents a watershed moment for a disease that kills more than 50,000 Americans annually.
Dr. Rachna Shroff, chief of hematology and oncology at the University of Arizona Cancer Center, said she cried tears of joy upon seeing the preliminary trial results. Shroff called the development unprecedented and a complete game changer for physicians treating pancreatic cancer patients. Pharmacologist Channing Der from the University of North Carolina described the approval as monumental, noting that pancreatic cancer ranks as the third leading cause of cancer death nationwide and the deadliest of all cancers.
Targeting Previously Untreatable Mutation
Taken as a daily pill, Rasonque targets a mutation in the KRAS gene found in nearly all pancreatic cancers and many lung, colorectal, and ovarian cancers. The gene functions like a cellular growth switch. The mutation locks it in the on position, causing uncontrolled cell growth. Scientists have pursued this target for years without success until now. The breakthrough ushers in what Shroff calls the start of a revolution in cancer treatment that will fundamentally change how physicians approach the disease.
The medication does produce significant side effects, including severe blistering rashes, mouth and throat sores, vomiting, and diarrhea. Former Nebraska Senator Ben Sasse, who received the drug during clinical trials, described the rash as nuclear in severity during a podcast interview this spring.
Price and Access Challenges Ahead
Revolution Medicines set the list price at $39,800 per month before insurance coverage and discounts. More than 2,000 patients have already received treatment through an expanded access program launched in May. Over 67,000 Americans will receive pancreatic cancer diagnoses this year, according to the American Cancer Society. The disease remains exceptionally difficult to treat because no screening exists and early symptoms prove so vague that most patients receive diagnoses at advanced stages. The five-year survival rate for the most common form stands at just 8 percent, making any treatment advancement critically important for patients and families facing this devastating diagnosis.